Regulatory Strategies / Expert Views
Regulations pertaining to pharmaceutical products are continuously changing...
Read More ➔Mexico is the second largest market for medicinal products and devices in Latin America. It is an emerging candidate regarding biologic drug regulation in the region and creates ample opportunities for the Mexican medical devices market. While Mexico’s regulatory body Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS, oversees regulation activities in the country the process for submission is time costly leading to a backlog of submissions.
As a leading global contender, DDReg’s Regulatory Services in Mexico provides on-going support and development of customized strategies during all regulatory phases while keeping track of the most recent regulatory requirements to ensure high quality and timely submissions. We deliver reliable safety measures, ensure risk mitigation, and collaborate with experts to facilitate effortless delivery of product launches, regulatory filing and market authorizations.
Regulations pertaining to pharmaceutical products are continuously changing...
Read More ➔Pharmaceuticals and other medicinal products need to be prior authorized by...
Read More ➔A gap analysis is a regulatory review process that identifies data gaps in the technical...
Read More ➔Regulatory issues arise unexpectedly and can create significant strain on a company’s...
Read More ➔DDReg provides expert consulting and efficient services for quality Drug Substance...
Read More ➔When it comes to regulatory strategies, CMC documentation play a crucial role in developing...
Read More ➔Managing the post-approval life cycle of a product is an essential component to sustaining...
Read More ➔Administrative documents are an integral component of regulatory submissions and constitute key certifications...
Read More ➔The regulatory approval pathway for Abbreviated New Drug Applications (ANDAs) is relatively complex....
Read More ➔